31-case review sharpens the clinical picture for canine SLO
Bottom line
Version 1
A new retrospective review in Veterinary Dermatology examined 31 dogs with symmetrical lupoid onychodystrophy, or SLO, and found that clinical diagnosis paired with history and presentation may be sufficient in many cases, without routine biopsy. The authors report favorable long-term outcomes with medical management and highlight a shift toward essential fatty acids while reducing reliance on tetracycline-based protocols. That adds a contemporary case series to a literature base that has historically been small and built largely on earlier reports of 18 to 30 dogs. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the paper reinforces a practical message: SLO remains a clinical disease first, marked by painful claw sloughing, onychomadesis, and chronic dystrophic regrowth, and treatment decisions often need to balance efficacy, cost, adherence, and the time needed for nails to regrow. Earlier reviews and knowledge summaries have already suggested benefit from essential fatty acids, doxycycline or tetracycline with niacinamide, and selective use of immunomodulatory therapy, but evidence has been limited and heterogeneous. A 31-case review that supports diagnosis without biopsy in typical presentations could help clinicians avoid more invasive workups in straightforward cases while still reserving biopsy for atypical or refractory disease. (pmc.ncbi.nlm.nih.gov)
What to watch: Watch for the full paper’s treatment breakdown, follow-up intervals, and any clearer guidance on when biopsy still changes management. (pmc.ncbi.nlm.nih.gov)
Key facts
- Study type
- Retrospective review
- Journal
- Veterinary Dermatology
- Sample size
- 31 dogs
- Condition
- Symmetrical lupoid onychodystrophy (SLO)
- Main finding
- Clinical diagnosis with history and presentation may be sufficient in many cases, without routine biopsy
- Treatment trend
- Essential fatty acids were used more, with reduced tetracycline use
- Outcome
- Long-term medical management appeared favorable
- Clinical signs
- Painful claw sloughing, onychomadesis, and chronic dystrophic regrowth
Version 2
A new retrospective study in Veterinary Dermatology reviews 31 cases of symmetrical lupoid onychodystrophy in dogs and points to two takeaways clinicians will notice right away: many cases can be diagnosed clinically, and long-term medical management appears to work well, especially with essential fatty acids in the treatment mix. According to the abstract, the authors also report declining tetracycline use, suggesting a shift in how clinicians are managing this painful, frustrating claw disease in practice. (pubmed.ncbi.nlm.nih.gov)
That matters because SLO has long been recognized as a distinctive but not especially common canine claw disorder, and the evidence base has been thin for years. Classic reports include an 18-case retrospective analysis published in 1995 and a 30-dog treatment review published in 2003, both of which helped define the syndrome and the range of therapies used. Subsequent reviews and clinical summaries have described SLO as an immune-mediated condition with possible genetic predisposition in some breeds, and one that typically presents with sloughing claws, pain, lameness, and abnormal regrowth across multiple feet. (pubmed.ncbi.nlm.nih.gov)
The new 31-case review appears to build on that history by focusing on real-world diagnosis, treatment protocols, and outcomes. Based on the abstract provided by Wiley’s table of contents listing, the authors support clinical diagnosis without biopsy and report favorable long-term results with medical treatment, particularly using essential fatty acids while reducing tetracycline use. That aligns with earlier literature showing that fatty-acid-based approaches have been part of SLO management for decades, including a small 1998 report of successful long-term treatment with omega-3 and omega-6 fatty acids and later reviews comparing fatty acids with antimicrobial-niacinamide combinations and other immunomodulatory options. (onlinelibrary.wiley.com)
Outside the new paper, the broader literature helps explain why this is clinically relevant. A Canadian Veterinary Journal review on claw disease notes that biopsy can be challenging in SLO and that clinicians often rely on signalment, distribution, and characteristic nail changes, while also ruling out differentials such as infection, vasculitis, neoplasia, endocrinopathy, trauma, and dermatophytosis. The same review emphasizes that response assessment takes time and that treatment discussions with pet parents should account for the slow pace of nail regrowth and the possibility of relapse or persistent dystrophy even when pain improves. (pmc.ncbi.nlm.nih.gov)
Direct outside expert reaction to this specific paper was limited in publicly available sources, but published commentary in the field has been moving in a similar direction. A 2020 evidence summary in Veterinary Record concluded that oral essential fatty acids may be a reasonable option in some dogs, while also noting that the comparative evidence remains weak and largely retrospective. More recent review material in PubMed and open-access summaries likewise describes doxycycline or tetracycline with niacinamide as common choices, but not clearly superior across all cases, leaving room for less burdensome protocols when they are clinically effective. (bvajournals.onlinelibrary.wiley.com)
Why it matters: For veterinary teams, this study may be most useful not because it introduces a brand-new therapy, but because it supports simplification. If the full paper confirms that typical SLO cases can be diagnosed confidently without routine biopsy, that could reduce anesthesia, cost, and procedural morbidity in dogs with classic presentations. And if essential fatty acids featured prominently in successful long-term control, that may support more sustainable treatment plans for pet parents, especially when tetracycline-based regimens are difficult to source, administer, or tolerate over time. (pmc.ncbi.nlm.nih.gov)
There’s still an important caution here. SLO remains a diagnosis that depends on excluding mimics and recognizing when a case is atypical, infected, or refractory. Earlier reviews recommend biopsy or expanded workup when the presentation is not classic, when only a few claws are involved, or when dogs fail to respond as expected. So the practical takeaway is not “never biopsy,” but rather “biopsy selectively.” (pmc.ncbi.nlm.nih.gov)
What to watch: The next thing clinicians will want from the full publication is granularity: which protocols were used first-line, how outcomes were defined, how often secondary infections complicated care, and which cases still required biopsy or escalation to stronger immunomodulatory therapy. Those details will determine whether this paper changes everyday case management or mainly strengthens confidence in approaches many dermatology clinicians already use. (pubmed.ncbi.nlm.nih.gov)